Prediction of promiscuous epitopes in ORF2 of Hepatitis E virus: an In-Silico approach

Abstract

Background: Vaccine development against emerging infections is essentially important for saving people from increasing viral infections. In developing countries, Hepatitis E (HEV) is a common infection affecting millions of people worldwide. Based on In-silico analysis, different approaches have been targeted.
 Objectives: Rationale of this study is to design an epitope-based vaccine candidates with the help of immunoinformatics that can predict promiscuous B-cell and T-cell epitopes of the most antigenic HEV-ORF2 capsid protein.
 Materials & Methods: This study suggests potential T-cell and B-cell epitopes of the highly antigenic HEV ORF2 capsid protein while using various In-silico tools such as NCBI-BLAST, Expassy, CLC workbench, Ellipro and Discotope.
 Results: Potential antigenic and immunogenic CD8+ T-cell epitopes were predicted from the global consensus sequence of ORF2-HEV. Furthermore, twenty-two linear B-cell epitopes were predicted. Among these, “SLGAGPV” at position 587-593 and “LEFRNLTPGNTNTRVSRYSS” at position 306-325 were most antigenic with antigenicity score 1.4206 and 1.3600 respectively. Discontinuous B-cell epitopes were found by three-dimensional capsid protein structure. Epitopes predicted in this study reveal high antigenicity and promiscuity for HLA classes.
 Conclusion: Collectively, our data suggests promiscuous epitopes that can potentially acts as new candidates for the design of HEV peptide vaccine.
 Keywords: Virology; gastrointestinal disease.

Multi-epitope vaccine design for hepatitis E virus based on protein ORF2 and ORF3

“…In these studies, the parameter settings like the selected HLA range and the server threshold settings determine the final peptide selection. The selected peptides all differ between vaccine studies but effective immunoreactions have been induced using these different strategies ( Samavia et al, 2022 ; Anwar et al, 2023 ; Ikram et al, 2023 ). The findings of our study are novel in that ORF3 was included as an additional target along with ORF2.…”

“…Immunoinformatic methods have been successfully applied to multiple types of vaccines targeting different pathogens, including HPV, PEDV, Mycobacterium tuberculosis , SARS-CoV-2, and HEV ( Behmard et al, 2020 ; Samavia et al, 2022 ; Arega et al, 2023 ; Hou et al, 2023 ; Ikram et al, 2023 ; Tîrziu et al, 2023 ). Multi-epitope vaccines designed with this method will stimulate the CD4 + , CD8 + T-cell response and the B-cell response.…”

A novel multi-epitope peptide vaccine candidate targeting Hepatitis E virus: an in-silico approach

“…GGPGPGTIRYRPLVPN, AYTSWWHVTHRAAYLV, GGYGPGPGVGGAAAVP were the most potent epitopes with 0.92, 0.91 and 0.9 scores respectively. The complete in-silico Previous studies on anti-HEV vaccine mainly targeted the capsid protein (encoded by ORF2) (36) (37). For the first time we have included HEV ORF3, capsid protein and polyprotein all together for the construction of an efficient, multi-epitope in-silico vaccine construct against (which was not certified by peer review) is the author/funder.…”

“…Previous studies on anti-HEV vaccine mainly targeted the capsid protein (encoded by ORF2) (36)(37). For the first time we have included HEV ORF3, capsid protein and polyprotein all together for the construction of an efficient, multi-epitope in-silico vaccine construct against HEV.…”

Editorial I: So, who wins? It is still: NCDs 3; Infections 2

“…[36][37][38][39][40][41][42] The non-communicable diseases theme is then followed by infectious diseases, ranging from HIV, [43][44][45][46][47][48][49] the COVID-19 pandemic, [50][51][52][53][54][55][56][57] and others. [58][59][60][61][62][63][64][65][66] We conclude the issue with a hybrid of papers [67][68][69][70][71][72][73][74][75] akatogo of sorts! Finally, we wish to thank our volunteers; editorial team and board; reviewers, authors, readers; and partners through AJPP and others, who, in one way or another, contributed to the sustainability and growth of AHS, as we continue our struggle to enhance publication of high-quality health science papers in Africa, the diaspora, and beyond.…”